OEC

Class [005]
Pharmaceutical agents affecting DNA structure by targeting DNA structure to treat disease namely, monogenic diseases, namely, sickle cell anemia, cystic fibrosis, Huntington disease, Duchenne muscular dystrophy, cancer, infectious disease, namely, viruses and bacterial infections, immunological disorders, hematological conditions, haploinsufficiencies, namely, immunodeficiency, and MonoMac syndrome hepatic disease, namely, hepatitis, non-alcoholic fatty liver disease, cirrhosis, non-alcoholic steatohepatitis, liver fibroids, channelopathies, namely, epilepsy, ataxia, migraine, hyperekplexia, blindness, deafness, peripheral pain syndrome, long QT syndrome, Brugada syndrome endocrine disease, namely, growth and thyroid disorders, cardiovascular disease, reproductive disease, renal disease, musculo-skeletal system disease, bone disease, none of the foregoing pharmaceutical agents having omega fatty acids as an ingredient.